ABL Bio (XKRX:298380) Net Income (Continuing Operations) : ₩-38,952 Mil (TTM As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is ABL Bio Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. ABL Bio's Net Income (Continuing Operations) for the three months ended in Mar. 2024 was ₩-11,971 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2024 was ₩-38,952 Mil.

ABL Bio Net Income (Continuing Operations) Historical Data

The historical data trend for ABL Bio's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ABL Bio Net Income (Continuing Operations) Chart

ABL Bio Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income (Continuing Operations)

Get a 7-Day Free Trial

-37,004.63

-55,605.92

-43,557.94

3,208.63

-2,646.66

ABL Bio Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Income (Continuing Operations)	Get a 7-Day Free Trial															24,334.61	-10,358.34	-4,109.45	-12,513.49	-11,971.11

ABL Bio Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-38,952 Mil.

ABL Bio (XKRX:298380) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

ABL Bio Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of ABL Bio's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.

ABL Bio (XKRX:298380) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ABL Bio Inc (XKRX:298380) » Definitions » Net Income (Continuing Operations)

Comparable Companies

Traded in Other Exchanges

N/A

Address

2nd Floor, 16 Daewangpangyo-Ro 712, Beon-Gil, Bundang-Gu, Gyeonggi-do, Seongnam-si, KOR, 13488

Website

https://www.ablbio.com

ABL Bio Inc is a Korean biotech research company. The company is engaged in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline products include ABL001 an Bispecific Antibody, ABL201-205 an Antibody Drug Conjugate, T cell engager, Dual Immune Cell Targeting BsAb an Immuno-Oncology, ABL301 an BBB-Penetrating Bispecific Antibody.

ABL Bio (XKRX:298380) Headlines

No Headlines